These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 18283605)

  • 1. Monoclonal antibodies against components of the IGF system for cancer treatment.
    Feng Y; Dimitrov DS
    Curr Opin Drug Discov Devel; 2008 Mar; 11(2):178-85. PubMed ID: 18283605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
    Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
    Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer.
    Hofmann F; García-Echeverría C
    Drug Discov Today; 2005 Aug; 10(15):1041-7. PubMed ID: 16055020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.
    Burtrum D; Zhu Z; Lu D; Anderson DM; Prewett M; Pereira DS; Bassi R; Abdullah R; Hooper AT; Koo H; Jimenez X; Johnson D; Apblett R; Kussie P; Bohlen P; Witte L; Hicklin DJ; Ludwig DL
    Cancer Res; 2003 Dec; 63(24):8912-21. PubMed ID: 14695208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review.
    Ozkan EE
    Mol Cell Endocrinol; 2011 Sep; 344(1-2):1-24. PubMed ID: 21782884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the insulin growth factor receptor 1.
    Arnaldez FI; Helman LJ
    Hematol Oncol Clin North Am; 2012 Jun; 26(3):527-42, vii-viii. PubMed ID: 22520978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors.
    Goya M; Miyamoto S; Nagai K; Ohki Y; Nakamura K; Shitara K; Maeda H; Sangai T; Kodama K; Endoh Y; Ishii G; Hasebe T; Yonou H; Hatano T; Ogawa Y; Ochiai A
    Cancer Res; 2004 Sep; 64(17):6252-8. PubMed ID: 15342412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human monoclonal antibody fragments binding to insulin-like growth factors I and II with picomolar affinity.
    Zhao Q; Feng Y; Zhu Z; Dimitrov DS
    Mol Cancer Ther; 2011 Sep; 10(9):1677-85. PubMed ID: 21750218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting insulin-like growth factor in breast cancer therapeutics.
    Karamouzis MV; Papavassiliou AG
    Crit Rev Oncol Hematol; 2012 Oct; 84(1):8-17. PubMed ID: 22424863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting of insulin-like growth factor-I receptor with a monoclonal antibody inhibits growth of hepatic metastases from human colon carcinoma in mice.
    Bauer TW; Fan F; Liu W; Camp ER; Yang A; Somcio RJ; Bucana CD; Singh R; Ellis LM
    Ann Surg Oncol; 2007 Oct; 14(10):2838-46. PubMed ID: 17653802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in targeting insulin-like growth factor signaling pathway in cancer treatment.
    You L; Liu C; Tang H; Liao Y; Fu S
    Curr Pharm Des; 2014; 20(17):2899-911. PubMed ID: 23944362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IGF-1R as an anti-cancer target--trials and tribulations.
    Chen HX; Sharon E
    Chin J Cancer; 2013 May; 32(5):242-52. PubMed ID: 23601239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of the insulin-like growth factor system on an estrogen-dependent cancer phenotype in the MCF-7 human breast cancer cell line.
    Bradley LM; Gierthy JF; Pentecost BT
    J Steroid Biochem Mol Biol; 2008 Mar; 109(1-2):185-96. PubMed ID: 18337089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions.
    Gualberto A; Pollak M
    Oncogene; 2009 Aug; 28(34):3009-21. PubMed ID: 19581933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. State of the art and future perspectives for the use of insulin-like growth factor receptor 1 (IGF-1R) targeted treatment strategies in solid tumors.
    Scartozzi M; Bianconi M; Maccaroni E; Giampieri R; Del Prete M; Berardi R; Cascinu S
    Discov Med; 2011 Feb; 11(57):144-53. PubMed ID: 21356169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the insulin-like growth factor signaling pathway: figitumumab and other novel anticancer strategies.
    Yap TA; Olmos D; Molife LR; de Bono JS
    Expert Opin Investig Drugs; 2011 Sep; 20(9):1293-304. PubMed ID: 21777167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
    Sachdev D; Li SL; Hartell JS; Fujita-Yamaguchi Y; Miller JS; Yee D
    Cancer Res; 2003 Feb; 63(3):627-35. PubMed ID: 12566306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Id1-induced IGF-II and its autocrine/endocrine promotion of esophageal cancer progression and chemoresistance--implications for IGF-II and IGF-IR-targeted therapy.
    Li B; Tsao SW; Chan KW; Ludwig DL; Novosyadlyy R; Li YY; He QY; Cheung AL
    Clin Cancer Res; 2014 May; 20(10):2651-62. PubMed ID: 24599933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical development of inhibitors of the insulin-like growth factor receptor in oncology.
    Gualberto A; Pollak M
    Curr Drug Targets; 2009 Oct; 10(10):923-36. PubMed ID: 19663769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the insulin-like growth factor axis as a cancer therapy.
    Haddad T; Yee D
    Future Oncol; 2006 Feb; 2(1):101-10. PubMed ID: 16556077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.